Overview
STOK market data
Price History
STOK price chart · 1M
- O
- 33.14
- H
- 33.15
- L
- 32.21
- C
- 32.64
- Vol
- 68,471.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $33.14
- Previous Close
- $33.10
- Day High
- $33.15
- Day Low
- $32.21
- 52 Week High
- $34.87
- 52 Week Low
- $27.38
- 7 Day Return
- +3.87%
- 30 Day Return
- +11.15%
- 90 Day Return
- +5.67%
- 1 Year Return
- +0.66%
- Daily Notional Volume
- $2.2M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.12 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.23 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -753.6% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $18.00 – $40.22 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $2B · P/B 5.14 · P/S 73.80.
Company News
JP Morgan Reinstates Overweight on Stoke Therapeutics, Announces $40 Price TargetBenzinga · Aug 21, 2026, 7:06 PM
Guggenheim Reiterates Buy on Stoke Therapeutics, Maintains $60 Price TargetBenzinga · Aug 4, 2026, 2:07 PM
These Analysts Revise Their Forecasts On Stoke Therapeutics After Q2 ResultsBenzinga · Aug 4, 2026, 1:28 PM
Wedbush Maintains Outperform on Stoke Therapeutics, Raises Price Target to $40Benzinga · Aug 4, 2026, 12:48 PM
Canaccord Genuity Maintains Buy on Stoke Therapeutics, Lowers Price Target to $58Benzinga · Aug 4, 2026, 12:18 PM
Stoke Therapeutics Files Prospectus For Up To $200M ATM Stock Offering; Replaces Prior Program After Selling 4.7M Shares For $146.4M In Net ProceedsBenzinga · Aug 3, 2026, 9:07 PM
8-K filing — Stoke Therapeutics, Inc. (STOK)SEC EDGAR · Aug 3, 2026, 9:06 PM
Stoke To Participate In Pre-NDA FDA Meeting During 2H 2026 As It Plans To Initiate Planned Rolling NDA Submission For Zorevunersen In Q1 2027Benzinga · Aug 3, 2026, 8:04 PM
Stoke Therapeutics Q2 EPS $(0.93) Misses $(0.80) Estimate, Sales $9.325M Beat $6.044M EstimateBenzinga · Aug 3, 2026, 8:02 PM
Goldman Sachs Initiates Coverage On Stoke Therapeutics with Buy Rating, Announces Price Target of $44Benzinga · Jul 13, 2026, 9:43 AM